Production Method 1

877125-98-9

Reaction Conditions

1.1 Reagents: Sodium azide Solvents: Dimethylformamide ;  0.5 h, rt
1.2 Reagents: Triphenylphosphine ,  Water Solvents: Tetrahydrofuran ,  Water ;  23 h, rt

Reference

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

Irie, Osamu; et al, Bioorganic & Medicinal Chemistry Letters, 2008, 18(19), 5280-5284

Production Method 2

105-53-3

877125-96-7

877125-98-9

Reaction Conditions

1.1 Reagents: Tosyl chloride ,  Trimethylammonium chloride Solvents: Dichloromethane ;  1 h, 0 °C
1.2 Reagents: Sodium hydride Solvents: Tetrahydrofuran ;  3 h, rt → 60 °C
1.3 Reagents: Lithium chloride Solvents: Dimethyl sulfoxide ,  Water ;  10 h, 185 °C
2.1 Reagents: Lithium aluminum hydride Solvents: Tetrahydrofuran ;  0.5 h, 0 °C
3.1 Reagents: Triethylamine ,  Trimethylammonium chloride Solvents: Dichloromethane ;  1 h, rt
4.1 Reagents: Sodium azide Solvents: Dimethylformamide ;  0.5 h, rt
4.2 Reagents: Triphenylphosphine ,  Water Solvents: Tetrahydrofuran ,  Water ;  23 h, rt

Reference

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

Irie, Osamu; et al, Bioorganic & Medicinal Chemistry Letters, 2008, 18(19), 5280-5284

Production Method 3

1082373-80-5

877125-98-9

Reaction Conditions

1.1 Reagents: Triethylamine ,  Trimethylammonium chloride Solvents: Dichloromethane ;  1 h, rt
2.1 Reagents: Sodium azide Solvents: Dimethylformamide ;  0.5 h, rt
2.2 Reagents: Triphenylphosphine ,  Water Solvents: Tetrahydrofuran ,  Water ;  23 h, rt

Reference

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

Irie, Osamu; et al, Bioorganic & Medicinal Chemistry Letters, 2008, 18(19), 5280-5284

Production Method 4

1180557-08-7

877125-98-9

Reaction Conditions

1.1 Reagents: Lithium aluminum hydride Solvents: Tetrahydrofuran ;  0.5 h, 0 °C
2.1 Reagents: Triethylamine ,  Trimethylammonium chloride Solvents: Dichloromethane ;  1 h, rt
3.1 Reagents: Sodium azide Solvents: Dimethylformamide ;  0.5 h, rt
3.2 Reagents: Triphenylphosphine ,  Water Solvents: Tetrahydrofuran ,  Water ;  23 h, rt

Reference

Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-Cyanopyrimidines. Part 2

Irie, Osamu; et al, Bioorganic & Medicinal Chemistry Letters, 2008, 18(19), 5280-5284

{spiro[3.5]nonan-7-yl}methanamine Raw materials

• 1,3-diethyl propanedioate
• 2,2'-(Cyclobutane-1,1-diyl)diethanol
• 7-Hydroxymethyl-spiro3.5nonane
• Spiro[3.5]nonane-7-carboxylic acid, methyl ester

{spiro[3.5]nonan-7-yl}methanamine Preparation Products

• {spiro[3.5]nonan-7-yl}methanamine (877125-98-9)

• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615

Recent Advances in the Study of Spiro[3.5]nonan-7-yl Methanamine (CAS: 877125-98-9) and Its Applications in Chemical Biology and Medicine

The compound {spiro[3.5]nonan-7-yl}methanamine (CAS: 877125-98-9) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The spirocyclic structure of this molecule offers a rigid scaffold that can be leveraged for the design of novel bioactive molecules, making it a valuable target for further investigation.

Recent studies have highlighted the synthetic challenges and innovative approaches to producing {spiro[3.5]nonan-7-yl}methanamine with high purity and yield. Researchers have employed advanced catalytic methods, including asymmetric hydrogenation and ring-closing metathesis, to achieve efficient synthesis routes. These methods not only improve the scalability of production but also enable the introduction of diverse functional groups, thereby expanding the compound's utility in drug discovery. The compound's amine functionality further enhances its versatility, allowing for easy derivatization and conjugation with other pharmacophores.

In terms of biological activity, preliminary in vitro and in vivo studies have demonstrated that {spiro[3.5]nonan-7-yl}methanamine exhibits promising interactions with various biological targets, including G-protein-coupled receptors (GPCRs) and ion channels. These interactions suggest potential applications in treating neurological disorders, such as anxiety and depression, as well as chronic pain conditions. Additionally, the compound's ability to modulate enzyme activity has sparked interest in its use as a tool compound for probing biochemical pathways and identifying new therapeutic targets.

One of the most exciting developments is the exploration of {spiro[3.5]nonan-7-yl}methanamine as a building block for the development of next-generation pharmaceuticals. Its spirocyclic core provides a three-dimensional framework that can enhance binding affinity and selectivity, addressing some of the limitations of traditional planar structures. Recent patent filings and preclinical studies indicate that derivatives of this compound are being evaluated for their pharmacokinetic properties, including bioavailability and metabolic stability, which are critical for advancing them into clinical trials.

Despite these advancements, challenges remain in optimizing the compound's pharmacological profile and minimizing off-target effects. Future research directions may include structure-activity relationship (SAR) studies to identify the most promising derivatives, as well as computational modeling to predict their interactions with biological targets. Collaborative efforts between academia and industry will be essential to accelerate the translation of these findings into viable therapeutic options.

In conclusion, {spiro[3.5]nonan-7-yl}methanamine (CAS: 877125-98-9) represents a compelling area of research with significant potential for impacting drug discovery and development. Its unique structural features, combined with its versatile reactivity and biological activity, make it a valuable candidate for further exploration. As the field continues to evolve, ongoing studies will likely uncover new applications and refine our understanding of this compound's therapeutic potential.

• 52580-60-6(Bicyclo[3.1.1]heptane-2-methanamine,6,6-dimethyl-, (1a,2a,5a)- (9CI))
• 201418-09-9(BICYCLO[3.1.1]HEPTANE-3-METHANAMINE, 2-ETHYL-6,6-DIMETHYL-)
• 61299-72-7(bicyclo[3.1.1]heptane-3-methanamine, 2,6,6-trimethyl-)
• 38235-68-6((1S,2R,5S)-6,6-Dimethylnorpinan-2-ylmethanamine)
• 581812-78-4(Bicyclo[3.1.1]heptane-6-methanamine, 2,2-dimethyl-)
• 655256-66-9(BICYCLO[3.1.1]HEPTANE-2-METHANAMINE, 6,6-DIMETHYL-, (1S,5S)-)
• 226878-99-5(Bicyclo[3.1.1]heptane-2-methanamine, 6,6-dimethyl-, (1R,2R,5R)-)
• 57357-85-4(Bicyclo[3.1.1]heptane-3-methanamine,2,6,6-trimethyl-, (1S,2S,3S,5R)-)
• 73522-42-6(BICYCLO[3.1.1]HEPTANE-2-METHANAMINE, 6,6-DIMETHYL-, (1S,2R,5S)-)
• 146377-53-9(Bicyclo[3.1.1]heptane-3-methanamine, 6,6-dimethyl-)